Home›Trial›NCT05308264
🔬NCT05308264Phase 1Phase 2RECRUITING

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Study Summary

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Conditions
Low Risk Myelodysplastic Syndromes
Interventions / Drugs
R906289 Monosodium (R289 Na)
View on ClinicalTrials.gov ↗
Sponsor
RIGL
Rigel Pharmaceuticals
Immunology
D39/100
Study Details
Enrollment86 participants
Primary Completion—
Lead SponsorRigel Pharmaceuticals
Data Retrieved2026-04-11 04:25:58.320487+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.